Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement

• Type of Material: Article
• Authors: Debbie Saslow, American Cancer Society; Kimberly S. Andrews, American Cancer Society; Deana Manassaram-Baptiste, American Cancer Society; Lacey Loomer, Emory University; Kristina E. Lam, Georgia Department of Public Health; Marcie Fisher-Borne, American Cancer Society; Robert Smith, Emory University; Elizabeth T. H. Fontham, Louisiana State University
• Language: English
• Date: 2016-09-01
• Publisher: American Cancer Society (ACS) Journals
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2016 American Cancer Society.
• Final Published Version (URL): http://dx.doi.org/10.3322/caac.21355
• Title of Journal or Parent Work: CA: A Cancer Journal for Clinicians
• Volume: 66
• Issue: 5
• Start Page: 375
• End Page: 385
• Grant/Funding Information: The American Cancer Society (ACS) supported the development of the guideline through the use of general funds. Outside the submitted work, the ACS is the recipient of 2 cooperative agreements from the Centers for Disease Control and Prevention (CDC), Prevention and Public Health Fund, that seek to increase human papillomavirus (HPV) vaccination of girls and boys ages 11 to 12 years within the United States.
• Keywords: vaccine; Papillomavirus Vaccines; American Cancer Society; guideline; human papillomavirus (HPV); Guidelines as Topic; United States; cancer prevention; Humans; Vaccination; Papillomavirus Infections; Advisory Committee on Immunization Practices
• Research Categories: Health Sciences, Epidemiology; Health Sciences, Obstetrics and Gynecology; Health Sciences, Oncology

Abstract

Answer questions and earn CME/CNE. The American Cancer Society (ACS) reviewed and updated its guideline on human papillomavirus (HPV) vaccination based on a methodologic and content review of the Advisory Committee on Immunization Practices (ACIP) HPV vaccination recommendations. A literature review was performed to supplement the evidence considered by the ACIP and to address new vaccine formulations and recommendations as well as new data on population outcomes since publication of the 2007 ACS guideline. The ACS Guideline Development Group determined that the evidence supports ACS endorsement of the ACIP recommendations, with one qualifying statement related to late vaccination. The ACS recommends vaccination of all children at ages 11 and 12 years to protect against HPV infections that lead to several cancers and precancers. Late vaccination for those not vaccinated at the recommended ages should be completed as soon as possible, and individuals should be informed that vaccination may not be effective at older ages.